Stepping on Roche's toes, Merck cuts into SCLC niche with third-line Keytruda OK
In the increasingly crowded checkpoint race, small cell lung cancer has been a rare area where Roche, a second runner-up, has a lead over the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
